FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/New Study Investigates How Fasting and Tirzepatide Impact Stomach Contents in Diabetes and Obesity
返回研究图书馆

New Study Investigates How Fasting and Tirzepatide Impact Stomach Contents in Diabetes and Obesity

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

New Study Investigates How Fasting and Tirzepatide Impact Stomach Contents in Diabetes and Obesity

A recent study launched by Eli Lilly and Company aims to explore how fasting duration and withholding of tirzepatide—a popular peptide therapy—impact stomach contents after a meal. The findings could offer valuable insights into the effectiveness and mechanisms of this treatment, particularly for individuals with type 2 diabetes mellitus (T2DM) or those struggling with obesity without T2DM.

Background

Peptide therapies have gained significant traction in recent years due to their potential benefits in managing chronic conditions like diabetes and obesity. Tirzepatide, one such therapy, has shown promise in clinical trials for its ability to control blood sugar levels and promote weight loss. However, understanding how various factors, including fasting times and drug discontinuation, affect the body's response is crucial.

This study, which can be found on ClinicalTrials.gov (NCT07299084), marks an important step in unraveling these dynamics. By using ultrasound technology to measure stomach contents post-meal, researchers aim to provide a clearer picture of how tirzepatide interacts with the digestive system under different conditions.

Key Details

The study is currently active but not recruiting participants, indicating that it has moved past its initial phases and is likely collecting data. Sponsored by Eli Lilly and Company, this Phase 1 clinical trial focuses on evaluating the effect of fasting duration and tirzepatide withholding on stomach content volume in two distinct groups: individuals with T2DM and those without diabetes but who are overweight or obese.

Participants will undergo a test meal scenario where ultrasound scans will be used to measure the amount of food and fluid remaining in their stomachs. The study is designed to shed light on how different fasting periods and pauses in taking tirzepatide influence gastric emptying rates, which could have significant implications for treatment regimens and patient care.

Key Takeaways

  • Understanding Gastric Emptying: This research provides a deeper understanding of how fasting and drug discontinuation affect the rate at which food leaves the stomach.
  • Clinical Utility of Tirzepatide: By examining tirzepatide's effects in both diabetic and non-diabetic obese populations, this study offers critical insights into its broader clinical utility.
  • Regulatory Implications: Data from this trial could influence FDA regulations regarding medication administration guidelines for patients using peptide therapies like tirzepatide.
  • Patient Care Strategies: Insights gained may lead to more personalized treatment plans that account for fasting and drug adherence factors, enhancing patient outcomes.

What This Means

For the peptide community, including researchers, clinicians, and informed consumers, this study underscores the importance of continuous research into how these innovative treatments work in real-world scenarios. Understanding the nuances of gastric emptying under varying conditions can lead to more effective therapeutic strategies and better management of chronic diseases such as diabetes and obesity.

Moreover, the findings could pave the way for future studies that delve even deeper into the mechanisms behind peptide therapies, ultimately contributing to advancements in personalized medicine and improved patient care across various health disciplines.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。